Drug Database
Back to search

Belgium· BE-AMP-SAM460311-00

Levobupivacaïne Fresenius Kabi 1.25 mg/ml

A levobupivacaine product containing levobupivacaine hydrochloride, registered in Belgium by Fresenius Kabi. The same ATC class is registered in 10 of our 19 countries.

ATC N01BB10

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedLevobupivacaïne Fresenius Kabi 1.25 m…ATCN01BB10REGISTER NO.BE-AMP-SAM460311-00PACKS LISTED1CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about levobupivacaine hydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Levobupivacaine is registered in 10 of 19 countries.

Countries holding a registration under ATC N01BB10 (levobupivacaine), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 6 of them publish a price we can compare per daily dose
Search levobupivacaine products by name

Levobupivacaine · ATC N01BB10

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Ireland
  • Netherlands
  • Polandprice
  • Spainprice
  • Sweden
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Levobupivacaine Hydrochloride
Manufacturer
Fresenius Kabi
Country
Belgium (BE)
ATC code
N01BB10
ATC class
Levobupivacaine
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    3264363

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

101 interactions on record for levobupivacaine.

Graded by severity as the source publishes them — 73 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check levobupivacaine against other medicinesHow interaction checks work

Levobupivacaine · interactions on record

101 records

  • 73 moderate
  • 28 minor

Most severe, free to view

  • ClotrimazoleA01AB18moderate
  • LidocainA01AE01moderate
  • CimetidineA02BA01moderate
  • AprepitantA04AD12moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Levobupivacaine in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All levobupivacaine products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Czechia · Levobupivacaine Kabi
  • Spain · Levobupivacaína Altan, Levobupivacaína Kabi
  • France · Levobupivacaine Altan, Levobupivacaine Kabi
  • United Kingdom (Northern Ireland) · Levobupivacaine, Levobupivacaine Altan
  • Croatia · Levobupivakain Kabi
  • Ireland · Levobupivacaine
  • Italy · Levobupivacaina Altan, Levobupivacaina Bioindustria L.I.M
  • Netherlands · Levobupivacaïne Fresenius Kabi, Levobupivacaïne Molteni
  • Poland · Levobupivacaine Molteni
  • Portugal · Levobupivacaína Altan, Levobupivacaína Kabi
  • Sweden · Levobupivacaine Molteni
  • Slovenia · Levobupivakain Kabi
  • Slovakia · Levobupivacaine Kabi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cceff397-6e79-4188-aee7-9fa5a75d5adb
GET /v1/drugs/cceff397-6e79-4188-aee7-9fa5a75d5adb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Levobupivacaïne Fresenius Kabi 1.25 mg/ml",
  "name_fr": "Levobupivacaïne Fresenius Kabi 1.25 mg/ml",
  "name_nl": "Levobupivacaïne Fresenius Kabi 1.25 mg/ml",
  "amp_code": "SAM460311-00",
  "strengths": [
    "1.4100",
    "1.2500",
    "9.1490"
  ],
  "pack_count": 3,
  "substances": [
    "Levobupivacaine Hydrochloride",
    "Levobupivacaine",
    "Sodium Chloride",
    "Sodium Hydroxide"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Levobupivacaine",
  "authorisation_numbers": [
    "BE460311"
  ]
}
API referenceMCP serverPlans

See everything about levobupivacaine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console